Distinctive effect of 6% hydroxyethyl starch 130/0.4 (Voluven) infusion on pediatric patients with congenital heart disease.
It has not been clear that Voluven (6% hydroxyethyl starch 130/0.4) may be administered in pediatric patients safely. The purpose of this study was to determine if Voluven could be used for blood volume expansion and hypovolemia prevention in pediatric patients with congenital heart disease. 50 pediatric patients with congenital heart disease were recruited in the study. Circulatory and respiratory parameters were determined to monitor the responses to intravenous infusion of Voluven in the patients. Intravenous infusion of Voluven significantly increased levels of colloid osmotic pressure and central venous pressure, but decreased levels of hemoglobin in the patients. Voluven infusion did not significantly affect colloid osmotic pressure, central venous pressure, hemoglobin and heart rate in the preschool children (<6 years old), and similarly, low infusion (100-240 mL per patient) of Voluven did not significantly affect colloid osmotic pressure, central venous pressure, hemoglobin and heart rate in the young child patients. Also, there was the similar response, i.e. increased colloid osmotic pressure, to Voluven infusion in both female child patients and patients with atrial septal defect. Voluven may be used in pediatric patients with congenital heart disease, but not in the preschool child patients. Furthermore, special attention should be paid to the intravenous administration of Voluven for blood volume expansion and hypovolemia prevention in female pediatric patients and child patients with atrial septal defect.